These results largely suggest that βArr2 signaling does not drive MOR-mediated antinociceptive tolerance, respiratory depression, constipation, or reward and do not support the development of G-protein biased compounds as a broadly effective strategy to reduce side effects. The gene discussed is OPRM1; the disease is Respiratory insufficiency due to muscle weakness.